The purpose of this study was to develop a MR imaging markers for quantitative assessment of liver fibrosis and validate the method. Both normal monkeys and monkeys with non-alcoholic steatohepatitis were used for the validation study compared to histopathology of liver biopsy specimens. Liver extracellular volume was quantified and correlated strongly with biopsy fibrosis scores.
Seven (7) normal and eleven (11) monkeys with NASH were used in this validation study. The monkeys were scanned supine in a 1.5 T Siemens Aeria system (Siemens Medical Solutions, Malvern, PA), after anesthesia and intubation. The MRI protocol includes scout imaging and pre-contrast and post-contrast T1 mapping (10 min after the contrast injection) using the cardiac MR MOLLI T1 mapping sequences. The basic imaging parameters for T1 mapping were: TR/TE = 2.8/1.4 msec, field-of-view = 200 x 175 mm2, matrix = 176 x 154 (interpolated), slice thickness = 5 mm, acquisition time for each slice = 22 - 24 sec. Typically, 4-6 slices were obtained to cover the entire liver. A single dose of 0.1 mmol/kg Magnevist (Bayer HealthCare, Whippany, NJ) was injected for post-contrast imaging. The biopsies of both normal and NASH monkeys were performed within 8 weeks of the MRI scans. The histopathology (Sirius red stain) of the tissue was reviewed and scored for fibrosis (score from 1 to 4) independently by a pathologist, who was blind to MRI results. The MRI analysis was performed by another reviewer who was blind to biopsy results. Liver extracellular volume (LECV), as an imaging marker for fibrosis, was calculated by following equation, on a pixel-by-pixel basis:
$$LECV=(1-HCT)\frac{\frac{1}{T1_{post-liver}}-\frac{1}{T1_{pre-liver}}}{\frac{1}{T1_{post-blood}}-\frac{1}{T1_{pre-blood}}}$$
Where HCT is the hematocrit that was determined by blood sampling. The LECV measurements were performed by a region-of-interest on the LECV maps at the approximately same locations of biopsies.
Figure 2 Significantly increased LECV in NASH monkeys